Company secured $55 million in financing to advance its clinical pipeline, stock showed strong upward momentum (up 540% over 12 months), trading above all major moving averages with bullish technical indicators (MACD positive, golden cross), and carries a Strong Buy analyst consensus with $13.50 price target. The financing announcement and technical strength drove Friday's 9.84% gain.
Also mentions QTTB
Articles that tag QTTB but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
